Anacor Pharmaceuticals, Inc. (ANAC)

99.20
NASDAQ
Prev Close 99.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Anacor Pharmaceuticals Reports Second Quarter 2013 Financial Results

Anacor Pharmaceuticals Reports Second Quarter 2013 Financial Results

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the second quarter ended June 30, 2013.

Anacor Pharmaceuticals Announces Second Quarter 2013 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces Second Quarter 2013 Financial Results Conference Call And Webcast

Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the second quarter ended June 30, 2013, on Thursday, August 8, 2013 at approximately 4:00 p.

Anacor Pharmaceuticals To Host Investor Day In New York

Anacor Pharmaceuticals To Host Investor Day In New York

Anacor Pharmaceuticals (NASDAQ:ANAC) will host an Investor Day for institutional investors and research analysts on Monday August 5, 2013 from approximately 12:00 p.

Anacor Pharmaceuticals Announces That It Has Submitted A New Drug Application To The FDA For Tavaborole

Anacor Pharmaceuticals Announces That It Has Submitted A New Drug Application To The FDA For Tavaborole

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that on July 26, 2013 it submitted its New Drug Application (NDA) to the U.

Anacor Pharmaceuticals Stock Sees Short Interest Increase 15%

Anacor Pharmaceuticals Stock Sees Short Interest Increase 15%

The most recent short interest data has been released by the NASDAQ for the 07/15/2013 settlement date, which shows a 366,968 share increase in total short interest for Anacor Pharmaceuticals Inc , to 2,810,388, an increase of 15.02% since 06/28/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Anacor Pharmaceuticals To Present Pivotal Phase 3 Data Of Tavaborole For The Topical Treatment Of Toenail Onychomycosis

Anacor Pharmaceuticals To Present Pivotal Phase 3 Data Of Tavaborole For The Topical Treatment Of Toenail Onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract “ Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail ...

Anacor Pharmaceuticals To Present At The JMP Securities Healthcare Conference

Anacor Pharmaceuticals To Present At The JMP Securities Healthcare Conference

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the JMP Securities Healthcare Conference on Wednesday, July 10, 2013 ...

Top Insider Trades: ACW GEL ANAC PRIM

Top Insider Trades: ACW GEL ANAC PRIM

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

5 Health Care Stocks Under $10 Ready to Rip Higher

5 Health Care Stocks Under $10 Ready to Rip Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study Of AN2728 In Adolescents With Atopic Dermatitis

Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study Of AN2728 In Adolescents With Atopic Dermatitis

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728.

Anacor Pharmaceuticals To Hold Conference Call Tomorrow, March 21, 2013 At 8am ET / 5am PT To Discuss Preliminary Results From The Phase 2 Dose-Ranging Study Of AN2728 In The Treatment Of Adolescents With Atopic Dermatitis

Anacor Pharmaceuticals To Hold Conference Call Tomorrow, March 21, 2013 At 8am ET / 5am PT To Discuss Preliminary Results From The Phase 2 Dose-Ranging Study Of AN2728 In The Treatment Of Adolescents With Atopic Dermatitis

Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the Phase 2 dose-ranging study of AN2728 in the treatment of adolescents with atopic dermatitis tomorrow, March 21, 2013 at approximately 7:00...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Anacor Pharmaceuticals Reports 2012 Fourth Quarter And Year-End Financial Results

Anacor Pharmaceuticals Reports 2012 Fourth Quarter And Year-End Financial Results

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2012.

Anacor Pharmaceuticals Announces 2012 Fourth Quarter And Year End Financial Results Conference Call And Webcast

Anacor Pharmaceuticals Announces 2012 Fourth Quarter And Year End Financial Results Conference Call And Webcast

Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the fourth quarter and year ended December 31, 2012, on Thursday, March 14, 2013 at approximately 4:00 p.

Anacor Pharmaceuticals Announces Positive Results From The Second Phase 3 Trial Of Tavaborole For Onychomycosis

Anacor Pharmaceuticals Announces Positive Results From The Second Phase 3 Trial Of Tavaborole For Onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

Anacor Pharmaceuticals To Present At The Cowen 33rd Annual Healthcare Conference

Anacor Pharmaceuticals To Present At The Cowen 33rd Annual Healthcare Conference

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the Cowen 33 rd Annual Healthcare Conference on Monday, March 4,...

Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta

Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

Anacor Falls On Positive But Disappointing Toenail Fungus Data

Anacor Falls On Positive But Disappointing Toenail Fungus Data

Anacor's phase III study is a success but cure rates are lower than expected.

Anacor Pharmaceuticals Announces Positive Results From The First Of Two Phase 3 Trials Of Tavaborole For Onychomycosis

Anacor Pharmaceuticals Announces Positive Results From The First Of Two Phase 3 Trials Of Tavaborole For Onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail...

Anacor Pharmaceuticals To Hold Conference Call Tomorrow, January 29, 2013 At 8AM ET To Discuss Preliminary Results From The First Phase 3 Study Of Tavaborole For The Treatment Of Onychomycosis

Anacor Pharmaceuticals To Hold Conference Call Tomorrow, January 29, 2013 At 8AM ET To Discuss Preliminary Results From The First Phase 3 Study Of Tavaborole For The Treatment Of Onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the first of two Phase 3 studies of tavaborole for onychomycosis tomorrow, January 29, 2013 at approximately 7:00 a.

Anacor Readies Results From Pivotal Study of Toenail Fungus Drug

Anacor Readies Results From Pivotal Study of Toenail Fungus Drug

Tavaborole study results expected any day.

Anacor Pharma: Run-Up Trade Into January Trial Data

Anacor Pharma: Run-Up Trade Into January Trial Data

Anacor will be releasing phase III results for a toenail fungus drug in January.

Two Speculative Biotech Buys

As M&A action heats up in the sector, consider two names that could shape up to be prime targets.

Del Monte, Anacor, CPI: Premarket Trading

Del Monte, Anacor, CPI: Premarket Trading

Del Monte Foods was gaining in premarket trading Friday after it agreed to a $4 billion private-equity buyout.